Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced that CEO and Executive Chairman Ehud Geller will present at the 2026 ThinkEquity Conference on Oct. 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. The presentation will provide an overview of the company’s GelrinC® technology, recent clinical developments, progress in its ongoing U.S. Food and Drug Administration (“FDA”) pivotal Phase III trial, and preparations for commercialization in Europe, where GelrinC has received CE Mark approval.
This announcement is significant because it offers investors and industry stakeholders a direct update on Regentis’ lead product, GelrinC, a cell-free, off-the-shelf hydrogel designed to regenerate knee cartilage. With approximately 470,000 cases of cartilage knee repair annually in the U.S. and no off-the-shelf treatment currently available, GelrinC could address a substantial unmet medical need. The company’s participation at a prominent investor conference underscores its commitment to transparency and engagement with the investment community as it advances toward potential commercialization.
The presentation comes at a critical juncture for Regentis. The ongoing FDA pivotal Phase III trial is a key milestone that could pave the way for U.S. market approval. Meanwhile, the CE Mark approval in Europe positions the company for near-term commercialization in that region. Geller and Chief Financial Officer Ori Gon will also be available for one-on-one meetings with investors, providing an opportunity for deeper discussions about the company’s strategy and financial outlook. For more details, the full press release can be viewed at https://ibn.fm/wicmT.
Regentis Biomaterials is dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue, including inflamed cartilage and bone. The company’s progress is closely monitored by investors, and updates are regularly available in its newsroom at https//ibn.fm/RGNT.
The conference presentation is also a platform for Regentis to showcase its potential to a broader audience. MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance visibility. As part of the Dynamic Brand Portfolio @ IBN, MissionIR delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. This broad reach ensures that Regentis’ developments are communicated effectively to investors, influencers, and the public.
For Regentis, the ThinkEquity Conference represents more than just a presentation; it is an opportunity to reinforce its narrative of innovation and progress. As the company moves closer to potential commercialization, each update on GelrinC’s clinical and regulatory journey is likely to be scrutinized by investors. The one-on-one meetings could also provide valuable insights into the company’s operational and financial strategies. With a clear focus on addressing a significant market need, Regentis Biomaterials is positioning itself as a noteworthy player in the regenerative medicine space.
